CN102292340B - 用作pde9 抑制剂的氨基-杂环类化合物 - Google Patents
用作pde9 抑制剂的氨基-杂环类化合物 Download PDFInfo
- Publication number
- CN102292340B CN102292340B CN201080005394.XA CN201080005394A CN102292340B CN 102292340 B CN102292340 B CN 102292340B CN 201080005394 A CN201080005394 A CN 201080005394A CN 102292340 B CN102292340 B CN 102292340B
- Authority
- CN
- China
- Prior art keywords
- pyrimidin
- dihydro
- pyrazolo
- ethyl
- cyclopentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Cc1ncccn1 Chemical compound *Cc1ncccn1 0.000 description 3
- UTALBSXROBFNSI-UHFFFAOYSA-N C(C1CNC1)c1ncccn1 Chemical compound C(C1CNC1)c1ncccn1 UTALBSXROBFNSI-UHFFFAOYSA-N 0.000 description 1
- QHTVYWFXDYYUAP-ZETCQYMHSA-N C(CNC1)[C@@H]1Oc1ncccn1 Chemical compound C(CNC1)[C@@H]1Oc1ncccn1 QHTVYWFXDYYUAP-ZETCQYMHSA-N 0.000 description 1
- HCZMCYRCAJKKLR-UHFFFAOYSA-N C(c1ccccc1)N(CC1)CC1c1ncccn1 Chemical compound C(c1ccccc1)N(CC1)CC1c1ncccn1 HCZMCYRCAJKKLR-UHFFFAOYSA-N 0.000 description 1
- ZDHWTWWXCXEGIC-UHFFFAOYSA-N C=Cc1ncccn1 Chemical compound C=Cc1ncccn1 ZDHWTWWXCXEGIC-UHFFFAOYSA-N 0.000 description 1
- ABLTZWIYELNTQQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1=Cc1ncccn1)=O Chemical compound CC(C)(C)OC(N(C1)CC1=Cc1ncccn1)=O ABLTZWIYELNTQQ-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1=O)=O VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- APCBTRDHCDOPNY-ZETCQYMHSA-N CC(C)(C)OC(N(CC1)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1O)=O APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 1
- ITMWYEKNIATPKN-JTQLQIEISA-N CC(C)(C)OC(N(CC1)C[C@H]1Oc1ncccn1)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1Oc1ncccn1)=O ITMWYEKNIATPKN-JTQLQIEISA-N 0.000 description 1
- SEOBJDCODJJFLV-UHFFFAOYSA-N CC(C)(C)OC(N1CC(Cc2ncccn2)C1)=O Chemical compound CC(C)(C)OC(N1CC(Cc2ncccn2)C1)=O SEOBJDCODJJFLV-UHFFFAOYSA-N 0.000 description 1
- KFPPPXHMKJPZPN-UHFFFAOYSA-N CC(c1cnc(C2CNCC2)nc1)P Chemical compound CC(c1cnc(C2CNCC2)nc1)P KFPPPXHMKJPZPN-UHFFFAOYSA-N 0.000 description 1
- VHLQGRGQUHOUHK-UHFFFAOYSA-N COCN(Cc1ccccc1)CS(C)(C)C Chemical compound COCN(Cc1ccccc1)CS(C)(C)C VHLQGRGQUHOUHK-UHFFFAOYSA-N 0.000 description 1
- RFVQRDCEALZTHS-SNVBAGLBSA-M C[C@H](C(N1)=NC([N-]C2CCOCC2)=C(C=N)C1=O)N(C1)CC1OS(C)(=O)=O Chemical compound C[C@H](C(N1)=NC([N-]C2CCOCC2)=C(C=N)C1=O)N(C1)CC1OS(C)(=O)=O RFVQRDCEALZTHS-SNVBAGLBSA-M 0.000 description 1
- NJPYDEOXYPCUHQ-UHFFFAOYSA-N N#Cc(cc1)ccc1OC1CNC1 Chemical compound N#Cc(cc1)ccc1OC1CNC1 NJPYDEOXYPCUHQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20609209P | 2009-01-26 | 2009-01-26 | |
| US61/206,092 | 2009-01-26 | ||
| PCT/IB2010/050133 WO2010084438A1 (en) | 2009-01-26 | 2010-01-13 | Amino-heterocyclic compounds used as pde9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102292340A CN102292340A (zh) | 2011-12-21 |
| CN102292340B true CN102292340B (zh) | 2015-05-06 |
Family
ID=42062324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080005394.XA Expired - Fee Related CN102292340B (zh) | 2009-01-26 | 2010-01-13 | 用作pde9 抑制剂的氨基-杂环类化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8278295B2 (enExample) |
| EP (1) | EP2389382B1 (enExample) |
| JP (1) | JP5656874B2 (enExample) |
| KR (1) | KR101417237B1 (enExample) |
| CN (1) | CN102292340B (enExample) |
| AR (1) | AR074966A1 (enExample) |
| AU (1) | AU2010207507B2 (enExample) |
| CA (1) | CA2748864C (enExample) |
| DK (1) | DK2389382T3 (enExample) |
| ES (1) | ES2420860T3 (enExample) |
| HR (1) | HRP20130530T1 (enExample) |
| IL (2) | IL213923A (enExample) |
| MX (1) | MX2011007862A (enExample) |
| PL (1) | PL2389382T3 (enExample) |
| PT (1) | PT2389382E (enExample) |
| SG (1) | SG172805A1 (enExample) |
| SI (1) | SI2389382T1 (enExample) |
| TW (1) | TWI404721B (enExample) |
| UY (1) | UY32391A (enExample) |
| WO (1) | WO2010084438A1 (enExample) |
| ZA (1) | ZA201105931B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11905293B2 (en) | 2017-05-22 | 2024-02-20 | Topadur Pharma Ag | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| MY173229A (en) | 2008-11-19 | 2020-01-07 | Forum Pharmaceuticals Inc | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| PT3029039T (pt) | 2010-05-17 | 2017-11-28 | Forum Pharmaceuticals Inc | Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado |
| CN103097383B (zh) | 2010-09-07 | 2015-09-16 | 安斯泰来制药株式会社 | 吡唑并喹啉化合物 |
| CN103097393B (zh) | 2010-09-07 | 2015-09-16 | 安斯泰来制药株式会社 | 喹喔啉化合物 |
| AU2012323085B2 (en) | 2011-10-10 | 2017-03-09 | H. Lundbeck A/S | PDE9i with imidazo pyrazinone backbone |
| AP2014007820A0 (en) | 2012-01-26 | 2014-07-31 | Lundbeck & Co As H | PDE9 inhibitors with imidazo triazinone backbone |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| TW201410244A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2908827A4 (en) * | 2012-10-19 | 2016-08-31 | Celus Pharmaceuticals Inc | VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE |
| CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
| CA2944714C (en) * | 2014-05-06 | 2023-05-16 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| BR112017000160A2 (pt) * | 2014-08-27 | 2017-10-31 | Hoffmann La Roche | derivados de azetidina substituidos como ligantes de taar |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| US10513524B2 (en) | 2015-07-07 | 2019-12-24 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| US10662146B2 (en) | 2015-09-15 | 2020-05-26 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
| CN105467028A (zh) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法 |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CA3025586A1 (en) | 2016-07-06 | 2018-01-11 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
| WO2018073251A1 (en) * | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| DK3532064T3 (da) | 2016-10-28 | 2020-08-24 | H Lundbeck As | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser |
| EP3532053A1 (en) | 2016-10-28 | 2019-09-04 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| CN109963834B (zh) | 2016-11-18 | 2023-04-14 | 综合研究实验室瑞典股份公司 | 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物 |
| MX390582B (es) | 2016-12-28 | 2025-03-20 | Dart Neuroscience Llc Star | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2) |
| AU2018225373C1 (en) * | 2017-02-23 | 2022-05-12 | Boehringer Ingelheim International Gmbh | New medical use of compound III |
| CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法 |
| RS65143B1 (sr) | 2017-05-26 | 2024-02-29 | Cardurion Pharmaceuticals Inc | Postupci izrade i upotrebe pde9 inhibitora |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| AU2018278422B2 (en) | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| AU2018276565A1 (en) * | 2017-06-01 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| EP3632437B1 (en) * | 2017-06-01 | 2024-03-13 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| MX2019014597A (es) | 2017-06-08 | 2020-02-05 | Merck Sharp & Dohme | Inhibidores de pirazolopirimidina de pde9. |
| KR102794907B1 (ko) | 2017-11-27 | 2025-04-14 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
| JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク． | ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態 |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| US12465601B2 (en) * | 2019-03-08 | 2025-11-11 | Transthera Sciences (Nanjing), Inc. | Uses of phosphodiesterase inhibitors |
| CN114450005A (zh) * | 2019-07-29 | 2022-05-06 | 星座制药公司 | 用于治疗神经障碍的化合物 |
| AU2023383105A1 (en) * | 2022-11-15 | 2025-05-29 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
| TW202523661A (zh) * | 2023-08-18 | 2025-06-16 | 天主教魯汶大學 | 新穎化合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| US20050176737A1 (en) * | 2001-12-06 | 2005-08-11 | Fraley Mark E. | Mitotic kinesin inhibitors |
| WO2008139293A1 (en) * | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2009121919A1 (en) * | 2008-04-02 | 2009-10-08 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| SE0103795D0 (sv) | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
| WO2003037432A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
-
2009
- 2009-12-31 TW TW098146481A patent/TWI404721B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 ES ES10701921T patent/ES2420860T3/es active Active
- 2010-01-13 CN CN201080005394.XA patent/CN102292340B/zh not_active Expired - Fee Related
- 2010-01-13 CA CA2748864A patent/CA2748864C/en not_active Expired - Fee Related
- 2010-01-13 KR KR1020117019758A patent/KR101417237B1/ko not_active Expired - Fee Related
- 2010-01-13 WO PCT/IB2010/050133 patent/WO2010084438A1/en not_active Ceased
- 2010-01-13 PL PL10701921T patent/PL2389382T3/pl unknown
- 2010-01-13 MX MX2011007862A patent/MX2011007862A/es active IP Right Grant
- 2010-01-13 JP JP2011547011A patent/JP5656874B2/ja not_active Expired - Fee Related
- 2010-01-13 DK DK10701921.8T patent/DK2389382T3/da active
- 2010-01-13 SI SI201030250T patent/SI2389382T1/sl unknown
- 2010-01-13 PT PT107019218T patent/PT2389382E/pt unknown
- 2010-01-13 HR HRP20130530AT patent/HRP20130530T1/hr unknown
- 2010-01-13 EP EP10701921.8A patent/EP2389382B1/en not_active Not-in-force
- 2010-01-13 AU AU2010207507A patent/AU2010207507B2/en not_active Ceased
- 2010-01-13 SG SG2011047594A patent/SG172805A1/en unknown
- 2010-01-25 UY UY0001032391A patent/UY32391A/es not_active Application Discontinuation
- 2010-01-25 AR ARP100100153A patent/AR074966A1/es unknown
- 2010-01-26 US US12/693,480 patent/US8278295B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 IL IL213923A patent/IL213923A/en not_active IP Right Cessation
- 2011-08-12 ZA ZA2011/05931A patent/ZA201105931B/en unknown
-
2012
- 2012-08-31 US US13/600,522 patent/US8618117B2/en not_active Expired - Fee Related
-
2013
- 2013-11-27 US US14/091,404 patent/US20140088081A1/en not_active Abandoned
-
2016
- 2016-07-21 IL IL246882A patent/IL246882A0/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| US20050176737A1 (en) * | 2001-12-06 | 2005-08-11 | Fraley Mark E. | Mitotic kinesin inhibitors |
| WO2008139293A1 (en) * | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2009121919A1 (en) * | 2008-04-02 | 2009-10-08 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11905293B2 (en) | 2017-05-22 | 2024-02-20 | Topadur Pharma Ag | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102292340B (zh) | 用作pde9 抑制剂的氨基-杂环类化合物 | |
| CN101687876B (zh) | 氨基杂环化合物 | |
| TWI629276B (zh) | 咪唑并嗒化合物 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| TWI616445B (zh) | 新穎環丙苯并呋喃基吡啶并吡二酮類 | |
| HK1163092B (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
| AU2011226819B2 (en) | Amino-heterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1163092 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1163092 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 Termination date: 20180113 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |